Grail released updated PATHFINDER study data showing improved positive predictive value for its multi-cancer blood test Galleri and announced performance metrics from a large U.S. cohort. The company reported higher rates of true positives among people with a positive test and that a substantial fraction of detected cancers were early-stage and outside existing screening programs. In a nearly 36,000-person PATHFINDER 2 cohort, Galleri’s sensitivity measured over a year was reported near 40% overall, with more than half of detected cancers found at stage 1 or 2. Positive predictive value climbed to roughly 62% in linked analyses, improving on earlier studies. Analysts noted these gains could strengthen Grail’s case to regulators and payers, but emphasized remaining questions about downstream diagnostic pathways, overdiagnosis risk, and real-world clinical utility.